Spotlight and Briefings

Back to feed
Spotlight 7 days 30 days 90 days 365 days

Navigate 7-day Briefings

2026-06-24 - 2026-06-30 ← Older
2026-07-03 - 2026-07-09 Newer →

WHO approves first Bundibugyo diagnostic test and launches treatment trial amid escalating outbreak

7 day briefing • 2026-07-01 - 2026-07-07 (2 weeks ago) • frozen

Spotlight this

This week saw critical advancements in the response to the Bundibugyo virus (BDBV) outbreak in the DRC and Uganda. The WHO added the first molecular diagnostic test for BDBV to its Emergency Use Listing (EUL) on 2 July, expanding testing capacity in the DRC from 200–400 tests per day at two sites to over 2000 tests per day across ten laboratories (S1). Concurrently, the PARTNERS platform trial began enrolling patients in the DRC to evaluate MBP134 monoclonal antibody and remdesivir as treatments, as no approved therapies exist for BVD (S2).

The WHO also released comprehensive clinical management guidelines for all filoviruses on 1 July, harmonizing approaches for Ebola, Marburg, Sudan, Bundibugyo, and Taï Forest viruses using GRADE methodology (S5). These developments follow the PHEIC declaration on 17 May 2026, with DRC reporting 1406 confirmed cases and 438 deaths as of 2 July (S1, S2). Despite the lack of a licensed vaccine for the Bundibugyo strain (S4), these diagnostic and therapeutic advances are crucial for outbreak control.

Navigate Timescales

7 days Current

2026-07-01 - 2026-07-07

30 days

2026-06-10 - 2026-07-09

90 days

2026-04-11 - 2026-07-09

365 days

2025-07-10 - 2026-07-09

Each tier targets the nearest available window end date to this briefing.

Pillar Signal Heatmap

Pillar 7d Trend
Outbreak Tracking
Transmission Dynamics
Medical Countermeasures
Humanitarian Response
Health Systems Resilience
Policy & Governance

Intensity is derived from pillar keyword overlap with headline, summary, key signals, and themes for each horizon.

Trend uses last 5 entries in this 7-day timescale (rightmost point is current).

Key Signals

  • - WHO added first molecular diagnostic test for Bundibugyo virus to Emergency Use Listing on 2 July 2026
  • - PARTNERS clinical trial for Bundibugyo virus disease treatments (MBP134 and remdesivir) began enrollment in DRC
  • - WHO released comprehensive filovirus clinical management guidelines covering all six species on 1 July 2026
  • - Diagnostic testing capacity in DRC expanded from 200–400 to over 2000 tests per day across ten laboratories
  • - DRC reported 1406 confirmed Bundibugyo cases and 438 deaths as of 2 July 2026
  • - No approved treatments or vaccines exist for Bundibugyo virus disease

Top Themes

bundibugyo-virus ebola-outbreak who-emergency-use-listing diagnostic-test clinical-trial monoclonal-antibody filovirus-guidelines drc-uganda

Key References

  1. WHO adds first molecular diagnostic test for Ebola Bundibugyo virus to Emergency Use Listing [rss]

    WHO announcement of first diagnostic test EUL for Bundibugyo virus, a concrete development with case and testing data

  2. PARTNERS clinical trial begins enrolment for Bundibugyo virus disease treatments in the Democratic Republic of the Congo [rss]

    PARTNERS trial enrollment start for Bundibugyo treatments, a critical step in therapeutic development

  3. WHO Guidelines for Clinical Management of Filovirus Disease (2026) [discovery_link]

    New WHO clinical management guidelines for all filoviruses, providing standardized treatment protocols

  4. No Vaccine: Managing the 2026 Bundibugyo Ebola Crisis [youtube]

    Context on the lack of a vaccine for the Bundibugyo strain, explaining the urgency of diagnostics and treatments